1H-NMR metabolomics reveals that astaxanthin nanoemulsion reverses liver damage by promoting restoration of energy and lipid metabolism
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04694-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von S Bautista-Hernández und 6 weiteren Autor:innen. Beteiligte Einrichtung: Doctorado en Ciencias Biomédicas, Universidad Veracruzana, Xalapa, Veracruz, México. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Lipid Metabolism, Liver, Energy Metabolism. Die Arbeit nennt 76 Literaturangaben.
Abstract (Originalsprache)
The therapeutic potential of astaxanthin is limited by its poor water solubility, which restricts its bioavailability and clinical translation. To overcome this limitation, an astaxanthin nanoemulsion (NEAX) was developed to enhance its oral delivery and hepatic targeting. The efficacy was evaluated in a hepatotoxicity model using physiological parameters and 1H-NMR serum metabolomics analyzed through Orthogonal Partial Least-Squares Discrimination Analysis (OPLS-DA). Wistar rats with thioacetamide-induced liver injury (150 mg/kg, i.p., twice weekly × 6 weeks) received oral astaxanthin (15 mg/kg) for 4 weeks as oil suspension (AX) or lecithin-based NEAX. Both treatments reduced serum transaminases, but only NEAX significantly increased hepatic antioxidant activity. The metabolomics analysis of biomarkers associated with liver damage and regeneration showed changes promoted by AX and NEAX. It also revealed that NEAX reversed liver damage by promoting restoration of metabolites involved in energy and lipid metabolism while limiting fatty acid β-oxidation and increasing metabolites associated with phospholipid insertion in the cellular membrane during liver regeneration, previously not reported for astaxanthin. These findings demonstrate that nanoemulsion delivery systems enhance the therapeutic effects of AX, advancing the development of hepatoprotective therapies based on nanoformulation strategies. They also highlight the potential of metabolomics to understand the mechanisms of hepatic damage and its treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Doctorado en Ciencias Biomédicas, Universidad Veracruzana, Xalapa, Veracruz, México.
- Centro de Investigación y Desarrollo en Alimentos, Universidad Veracruzana, Xalapa, Veracruz, México. lpascual@uv.mx.
- Instituto de Investigaciones Psicológicas, Universidad Veracruzana, Xalapa, Veracruz, México.
- Instituto de Salud Pública, Universidad Veracruzana, Xalapa, Veracruz, México.
- Centro de Investigación y Desarrollo en Alimentos, Universidad Veracruzana, Xalapa, Veracruz, México.
- Instituto de Química Aplicada, Universidad Veracruzana, Av. Dr. Luis Castelazo Ayala S/N, Col. Industrial-Ánimas, Xalapa, Veracruz, C.P. 91190, México.
Zitieren
APA
Bautista-Hernández, S., Pascual-Pineda, L. A., Herrera-Meza, S., García-Román, R., Jiménez-Fernández, M., García-Rodríguez, R. V., & Sánchez-Medina, A. (2025). 1H-NMR metabolomics reveals that astaxanthin nanoemulsion reverses liver damage by promoting restoration of energy and lipid metabolism. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04694-8
Vancouver
Bautista-Hernández S, Pascual-Pineda LA, Herrera-Meza S, García-Román R, Jiménez-Fernández M, García-Rodríguez RV, et al. 1H-NMR metabolomics reveals that astaxanthin nanoemulsion reverses liver damage by promoting restoration of energy and lipid metabolism. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04694-8
BibTeX
@article{BautistaHernndez2025,
author = {Bautista-Hernández, S and Pascual-Pineda, L A and Herrera-Meza, S and García-Román, R and Jiménez-Fernández, M and García-Rodríguez, R V and Sánchez-Medina, A},
title = {1H-NMR metabolomics reveals that astaxanthin nanoemulsion reverses liver damage by promoting restoration of energy and lipid metabolism},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04694-8}
}
EUVIMED